Pancreatic cancer is a very poor prognosis. It is caused in more than 80% of cases by oncogenic mutations of the protein called Kras. This mutated Kras protein is active by direct interaction of PI3K proteins. Until now, the subtype of Kras mutation was considered equivalent to causing pancreatic cancer by activating PI3K. This mini review exposes and discusses recent results of researchers in the USA: depending on the Kras mutation, the Kras-PI3K coupling is different. This work could lead to the use of targeted therapies tailored to the subtype.

Discover the article published :

Clin Res Hepatol Gastroenterol. 2020 Jun 24;S2210-7401(20)30166-2. doi: 10.1016/j.clinre.2020.05.021.The Type of KRAS Mutation Drives PI3Kα/γ Signalling Dependency: Implication for the Choice of Targeted Therapy in Pancreatic Adenocarcinoma Patients
Coralie Cayron 1 , Julie Guillermet-Guibert 2

Key words :

  • Signalisation,
  • cancer of the pancreas,
  • targeted therapies

Contact :

Coralie Cayron et Julie Guillermet-Guibert
Team : Eq 17 Julie Guillermet-Guibert
Mail : coralie.cayron@inserm.frjulie.guillermet@inserm.fr